Search results
'Extraordinary' study results offer new hope for advanced lung cancer patients being treated with...
USA TODAY via Yahoo News· 2 years agoPatients with advanced lung cancer had a better chance at survival when their treatment combined...
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated
Clinical Trials Arena via Yahoo Finance· 2 weeks agoThis week on Pipeline Moves, we kick off by looking at the termination of a Phase II...
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
Investor's Business Daily· 1 year agoIt's a new day at Bristol Myers Squibb, according to a company executive. But BMY stock remains...
15 Countries with the Highest Prostate Cancer Rates in the World
Insider Monkey via Yahoo Finance· 2 months agoIn this article, we will be taking a look at the 15 countries with the highest prostate cancer rates...
Advanced Lung Cancer and Immunotherapy
Verywell Health via Yahoo News· 8 months agoImmunotherapy is a newer class of treatment for lung and other cancers. It primes the body’s natural immune system to fight back against cancer....
15 Most Profitable Drugs In The World
Insider Monkey via Yahoo Finance· 11 months agoIn this article, we will be taking a look at the 15 most profitable drugs in the world. If you wish to see the top ones, feel free to skip our detailed...
Is Exelixis Stock a Buy Now?
Motley Fool· 1 year agoExelixis (NASDAQ: EXEL) is not the most popular drugmaker around, but there are several noteworthy things about this mid-cap stock. Second, Exelixis has...
5 questions facing pharma in 2024
BioPharma Dive via Yahoo Finance· 4 months agoNew drugs for obesity and cancer are the focus of many pharma companies, some of which are also grappling with how to manufacture complex cell and gene...
3 Things About Bristol Myers Squibb That Smart Investors Know
Motley Fool· 7 months agoBristol Myers Squibb (NYSE: BMY) shareholders have had a tough go of it lately, watching its shares...
1 Reason to Buy Exelixis Stock, and 1 Reason to Sell
Motley Fool· 2 years agoBiotech company Exelixis (NASDAQ: EXEL) is not the most famous name in the industry. If Exelixis can continue beating the market, investors would do well...
